Perspective Therapeutics, Inc. (CATX) – What Are Investment Firms Thinking About This Stock?

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.50.

Several equities research analysts have weighed in on CATX shares. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, September 15th. Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $14.00 to $4.00 in a research report on Monday, October 26th. BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Piper Sandler dropped their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, William Blair assumed coverage on Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CATX. Provenance Wealth Advisors LLC bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $44,000. Auctus Advisors LLC raised its stake in Perspective Therapeutics by 83.6% in the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after acquiring an additional 17,015 shares during the period. Taylor & Morgan Wealth Management LLC lifted its holdings in Perspective Therapeutics by 30.3% during the 3rd quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock valued at $236,000 after purchasing an additional 20,000 shares during the last quarter. Portland Investment Counsel Inc. bought a new position in Perspective Therapeutics during the second quarter worth $852,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Perspective Therapeutics in the second quarter valued at $1,015,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $0.79 on Friday. The business’s fifty day moving average is $2.38 and its two-hundred day moving average is $3.49. Perspective Therapeutics has a 52 week low of $0.78 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts expect that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.